Arlington Capital Partners Makes Majority Growth Investment in CBSET
October 1, 2025
Arlington Capital Partners completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (CBSET), a Boston-area provider of translational research and product development services for the medical device and life sciences markets. The investment is intended to help CBSET scale its integrated preclinical research and testing platform via capacity expansion and strategic add-on acquisitions.
- Buyers
- Arlington Capital Partners
- Targets
- Concord Biomedical Sciences and Emerging Technologies, Inc. (CBSET)
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Growth capital
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.